I think this is what Dr. Stewart was talking about.
Yes, absolutely, there is the opportunity for patients to continue on treatment after the clinical trial. That's through an extension protocol or an open label type of situation.
However, it is all dependent on the manufacturer being willing to continue to provide. That's the reality. We do require that they file a protocol as to how the patients would be treated, but we do a very efficient and timely review of that. Much of this timing and this gap is influenced by the manufacturer and what they are willing to do.